Background/Aim: Focal segmental glomerulosclerosis (FSGS) is a specific pattern of chronic renal injury with progressive glomerular scarring. The phenotypic alterations that contribute to FSGS include inflammatory response and oxidative stress. Astaxanthin (ATX) has a broad range of biological functions, particularly antioxidant and anti-inflammatory ones. This study was designed to evaluate the renoprotective effect of ATX treatment on Adriamycin-induced FSGS. Methods: In Balb/c mice, Adriamycin nephropathy was induced by Adriamycin (10 mg/kg body weight, diluted in normal saline) via a tail vein on day 0. Then the mice were treated with ATX (50 mg/kg body weight) once daily by oral gavage, again starting on the day of Adriamycin injection and continued for 6 weeks. At 6 weeks, the mice were sacrificed; kidneys and blood samples were collected for further analysis. Results: Animals that underwent intermittent exposure to ATX treatment exhibited significant improvements in renal functional parameters as well as in glomerular and interstitial fibrosis compared to those undergoing saline treatment in FSGS mouse models. ATX treatment exerted anti-inflammatory and antioxidant effects by promoting Nrf2 expression and suppressing renal nucleotide-binding oligomerization domain-like receptor protein 3 inflammasome activation. Conclusion: ATX might offer a ray of hope for ameliorating FSGS.

Keywords:
Astaxanthin, Adriamycin nephropathy, Focal segmental glomerulosclerosis, Nrf2, NLRP3
1.
Coppo R: Different targets for treating focal segmental glomerular sclerosis. Contrib Nephrol 2013,181:84-90.
2.
Bose B, Cattran D: Glomerular diseases: FSGS. Clin J Am Soc Nephrol 2014;9:626-632.
3.
Korbet SM: Treatment of primary FSGS in adults. J Am Soc Nephrol 2012;23:1769-1776.
4.
Yang SM, Chan YL, Hua KF, Chang JM, Chen HL, Tsai YJ, Hsu YJ, Chao LK, Feng-Ling Y, Tsai YL, et al: Osthole improves an accelerated focal segmental glomerulosclerosis model in the early stage by activating the Nrf2 antioxidant pathway and subsequently inhibiting NF-κB-mediated COX-2 expression and apoptosis. Free Radic Biol Med 2014;73:260-269.
5.
Wang M, Zhang J, Song X, Liu W, Zhang L, Wang X, Lv C: Astaxanthin ameliorates lung fibrosis in vivo and in vitro by preventing transdifferentiation, inhibiting proliferation, and promoting apoptosis of activated cells. Food Chem Toxicol 2013;56:450-458.
6.
Cheng X, Ku CH, Siow RC: Regulation of the Nrf2 antioxidant pathway by microRNAs: new players in micromanaging redox homeostasis. Free Radic Biol Med 2013;64:4-11.
7.
Ruiz S, Pergola PE, Zager RA, Vaziri ND: Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease. Kidney Int 2013;83:1029-1041.
8.
Zoja C, Benigni A, Remuzzi G: The Nrf2 pathway in the progression of renal disease. Nephrol Dial Transplant 2014;29(suppl 1): i19-i24.
9.
Yang SM, Hua KF, Lin YC, Chen A, Chang JM, Kuoping Chao L, Ho CL, Ka SM: Citral is renoprotective for focal segmental glomerulosclerosis by inhibiting oxidative stress and apoptosis and activating Nrf2 pathway in mice. PLoS One 2013;8:e74871.
10.
Sutterwala FS, Haasken S, Cassel SL: Mechanism of NLRP3 inflammasome activation. Ann NY Acad Sci 2014;1319:82-95.
11.
Leemans JC, Kors L, Anders HJ, Florquin S: Pattern recognition receptors and the inflammasome in kidney disease. Nat Rev Nephrol 2014;10:398-414.
12.
He L, Peng X, Zhu J, Chen X, Liu H, Tang C, Dong Z, Liu F, Peng Y: Mangiferin attenuate sepsis-induced acute kidney injury via antioxidant and anti-inflammatory effects. Am J Nephrol 2014;40:441-450.
13.
de Mik SM, Hoogduijn MJ, de Bruin RW, Dor FJ: Pathophysiology and treatment of focal segmental glomerulosclerosis: the role of animal models. BMC Nephrol 2013;14:74.
14.
Lui SL, Tsang R, Chan KW, Zhang F, Tam S, Yung S, Chan TM: Rapamycin attenuates the severity of murine adriamycin nephropathy. Am J Nephrol 2009;29:342-352.
15.
Chan KC, Pen PJ, Yin MC: Anticoagulatory and antiinflammatory effects of astaxanthin in diabetic rats. J Food Sci 2012;77:H76-H80.
16.
He L, Peng Y, Liu H, Yin W, Chen X, Peng X, Shao J, Liu Y, Liu F: Activation of the interleukin-4/signal transducer and activator of transcription 6 signaling pathway and homeodomain-interacting protein kinase 2 production by tonsillar mononuclear cells in IgA nephropathy. Am J Nephrol 2013;38:321-332.
17.
Farombi EO, Ekor M: Curcumin attenuates gentamicin-induced renal oxidative damage in rats. Food Chem Toxicol 2006;44:1443-1448.
18.
D'Agati VD, Kaskel FJ, Falk RJ: Focal segmental glomerulosclerosis. N Engl J Med 2011;365:2398-2411.
19.
Abreu CC, Cardozo LF, Mafra D: Could physical exercises modulate Nrf2-Keap1 pathway in chronic kidney disease? Med Hypotheses 2015:84:44-46.
20.
Aminzadeh MA, Reisman SA, Vaziri ND, Khazaeli M, Yuan J, Meyer CJ: The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores Nrf2 activity and attenuates oxidative stress, inflammation, and fibrosis in rats with chronic kidney disease. Xenobiotica 2014;44:570-578.
21.
Anders HJ, Muruve DA: The inflammasomes in kidney disease. J Am Soc Nephrol 2011;22:1007-1018.
22.
Vilaysane A, Chun J, Seamone ME, Wang W, Chin R, Hirota S, Li Y, Clark SA, Tschopp J, Trpkov K, et al: The NLRP3 inflammasome promotes renal inflammation and contributes to CKD. J Am Soc Nephrol 2010;21:1732-1744.
23.
Choi HD, Kim JH, Chang MJ, Kyu-Youn Y, Shin WG: Effects of astaxanthin on oxidative stress in overweight and obese adults. Phytother Res 2011;25:1813-1818.
24.
Sila A, Ghlissi Z, Kamoun Z, Makni M, Nasri M, Bougatef A, Sahnoun Z: Astaxanthin from shrimp by-products ameliorates nephropathy in diabetic rats. Eur J Nutr 2015;54:301-307.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.